NCT03195699View on ClinicalTrials.gov

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2024

Conditions

Breast CancerHead and Neck Squamous Cell CarcinomaNon Small Cell Lung CancerHepatocellular CancerColorectal CancerGastric AdenocarcinomaMelanomaAdvanced Cancer

Interventions

DRUG

TTI-101

Oral capsule

DRUG

TTI-101

Oral tablet

Trial Locations (2)

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

Mays Cancer Center at University of Texas Health Science Center SA, San Antonio

All Listed Sponsors

collaborator

M.D. Anderson Cancer Center

OTHER

lead

Tvardi Therapeutics, Incorporated

INDUSTRY

NCT03195699 - Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers | Biotech Hunter | Biotech Hunter